Literature DB >> 30509365

Cryoballoon antral pulmonary vein isolation vs contact force-sensing radiofrequency catheter ablation for pulmonary vein and posterior left atrial isolation in patients with persistent atrial fibrillation.

Miki Yokokawa1, Aman Chugh1, Rakesh Latchamsetty1, Hamid Ghanbari1, Thomas Crawford1, Krit Jongnarangsin1, Ryan Cunnane1, Mohammed Saeed1, Bipin Sunkara1, Mehmet Tezcan1, Frank Bogun1, Frank Pelosi1, Fred Morady1, Hakan Oral2.   

Abstract

BACKGROUND: The role of cryoballoon ablation (CBA) for antral pulmonary vein isolation (APVI) has not been well established in persistent atrial fibrillation (PerAF). Isolation of the left atrial posterior wall (BOX) after APVI has been suggested to improve the efficacy of radiofrequency catheter ablation (RFA) in PerAF.
OBJECTIVE: The purpose of this study was to compare characteristics and clinical outcomes of APVI by CBA vs APVI + BOX by contact force-guided RFA (CF-RFA) in patients with PerAF.
METHODS: APVI was performed in 167 consecutive patients with PerAF (mean age 64 ± 9 years; left atrial diameter 46 ± 6 mm) using CBA (n = 90) or CF-RFA (n = 77). After APVI, a roofline was created in 33 of 90 patients (37%) in the CBA group and BOX was performed in all 77 patients in the CF-RFA group.
RESULTS: During 21 ± 10 months of follow-up after a single ablation procedure, 37 of 90 patients (41%) in the CBA group (APVI) and 39 of 77 (51%) in the CF-RFA group (APVI + BOX) remained in sinus rhythm without antiarrhythmic drugs (AADs) (P = .22). During repeat ablation, APVI + BOX using CF-RFA was performed in 20 of 90 patients (22%) and in 18 of 77 patients (23%) who initially underwent CBA or CF-RFA, respectively. At 19 ± 10 months after repeat ablation, sinus rhythm was maintained in 55 of 90 patients (61%) and 52 of 77 patients (68%) in the CBA and CF-RFA groups without AADs, respectively (P = .39).
CONCLUSION: In PerAF, an initial approach of APVI by CBA or APVI + BOX by CF-RFA has a similar efficacy of 40%-50% without AADs. After repeat ablation for APVI + BOX by CF-RFA in ∼25%, sinus rhythm is maintained in 60%-70% of patients without AADs.
Copyright © 2018 Heart Rhythm Society. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Cryoablation; Cryoballoon; Posterior wall isolation; Radiofrequency

Mesh:

Year:  2018        PMID: 30509365     DOI: 10.1016/j.hrthm.2018.06.047

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  4 in total

1.  Comparison of cryoballoon and radiofrequency ablation for persistent atrial fibrillation: a systematic review and meta-analysis.

Authors:  Jitae A Kim; Mihail G Chelu
Journal:  J Interv Card Electrophysiol       Date:  2022-09-12       Impact factor: 1.759

2.  Cryoballoon Ablation versus Radiofrequency Ablation in Patients with Persistent Atrial Fibrillation (CRRF-PeAF): Protocol for a Prospective, Multicenter, Randomized, Controlled Study.

Authors:  Koji Miyamoto; Koshiro Kanaoka; Masue Yoh; Hiroki Takahashi; Jun Kishihara; Masahiro Ishikura; Yasuhiro Sasaki; Hiroshi Fukunaga; Takahiko Nagase; So Asano; Shingo Mizuno; Shintaro Yamagami; Yoshinao Yazaki; Takahiro Kusume; Yasuyuki Takada; Kenji Yodogawa; Wataru Shimizu; Takatoshi Shigeta; Yuichiro Sagawa; Yuko Inoue; Satoshi Nagase; Takeshi Aiba; Masahiko Takagi; Hidehira Fukaya; Atsushi Kobori; Junichi Nitta; Masato Murakami; Suguru Nishiuchi; Kazuhiro Satomi; Naoya Kataoka; Yu-Ki Iwasaki; Keiichi Ashikaga; Yasuteru Yamauchi; Kengo Kusano
Journal:  Int J Cardiol Heart Vasc       Date:  2022-06-25

3.  Effects of Hot Balloon vs. Cryoballoon Ablation for Atrial Fibrillation: A Systematic Review, Meta-Analysis, and Meta-Regression.

Authors:  Xinyi Peng; Xiao Liu; Hongbo Tian; Yu Chen; Xuexun Li
Journal:  Front Cardiovasc Med       Date:  2021-12-15

4.  Pulmonary vein isolation implemented by second-generation cryoballoon for treating hypertrophic cardiomyopathy patients with symptomatic atrial fibrillation: a case-control study.

Authors:  Zhong-Jing Cao; Xiao-Gang Guo; Qi Sun; Jian-Du Yang; Hui-Qiang Wei; Shu Zhang; Jian Ma
Journal:  J Geriatr Cardiol       Date:  2020-08       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.